UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2011
| | VENTRUS BIOSCIENCES, INC. | |
| | (Exact name of registrant as specified in its charter) | |
| Delaware | 001-35005 | 20-8729264 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer ID Number) |
| | |
99 Hudson Street, 5th Floor, New York, New York | 10013 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code | (646) 706-5208 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On November 14, 2011, Ventrus Biosciences, Inc. issued a press release to report top line results of a research study commissioned by Ventrus on the U.S. market for hemorrhoids and iferanserin (VEN-309), as well as give an update on the progress of its ongoing Phase III pivotal trial for VEN-109 for the treatment of asymptomatic hemorrhoids. A copy of the related press release and PowerPoint presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2 respectively and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| | |
| Exhibit No. | Description |
| | |
| 99.1 | Press release dated November 14, 2011. |
| 99.2 | Slide presentation of November 14, 2011. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | VENTRUS BIOSCIENCES, INC. | |
| | | |
| | | | |
| Date: November 14, 2011 | By: | /s/ David J. Barrett | |
| | | David J. Barrett, Chief Financial Officer | |
